S3 Guideline Urticaria. Part 2: Treatment of urticaria - German-language adaptation of the international S3 guideline.
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
02
08
2022
accepted:
12
09
2022
pubmed:
3
2
2023
medline:
25
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
This publication is the second part of the German-language S3 guideline on urticaria. It covers the management of urticaria and should be used together with Part 1 of the guideline on classification and diagnosis. This publication was prepared according to the criteria of the AWMF on the basis of the international English-language S3 guideline with special consideration of health system conditions in German-speaking countries. Chronic urticaria has a high impact on the quality of life and daily activities of patients. Therefore, if causal factors cannot be eliminated, effective symptomatic treatment is necessary. The recommended first-line treatment is to administer new generation, non-sedating H1 antihistamines. If the standard dose is not sufficiently effective, the dose should be increased up to fourfold. For patients who do not respond to this treatment, the second-line treatment in addition to antihistamines in the treatment algorithm is omalizumab and, if this treatment fails, ciclosporin. Other low-evidence therapeutic agents should only be used if all treatments in the treatment algorithm agreed upon by the guideline group fail. Both the benefit-risk profile and cost should be considered. Corticosteroids are not recommended for long-term treatment due to their inevitable severe side effects.
Substances chimiques
Histamine H1 Antagonists, Non-Sedating
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
202-215Informations de copyright
© 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734-766.
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines:1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383-394.
Kaminski-Hartenthaler A, Meerpohl JJ, Gartlehner G, et al. GRADE guidelines:14. Going from evidence to recommendations: the significance and presentation of recommendations. Z Evid Fortbild Qual Gesundhwes. 2014;108:413-420.
Grattan CE, Francis DM, Slater NG, et al. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet. 1992;339:1078-1080.
Kowalski ML, Woessner K, Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol. 2015;136:245-251.
Shakouri A, Compalati E, Lang DM, Khan DA. Effectiveness of Helicobacter pylori eradication in chronic urticaria:evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system. Curr Opin Allergy Clin Immunol. 2010;10:362-369.
Wedi B, Raap U, Wieczorek D, Kapp A. Urticaria and infections. Allergy Asthma Clin Immunol. 2009;5:10.
Ishaq S, Nunn L. Helicobacter pylori and gastric cancer:a state of the art review. Gastroenterol Hepatol Bed Bench. 2015;8:S6-S14.
Watanabe J, Shimamoto J, Kotani K. The effects of antibiotics for Helicobacter pylori eradication or dapsone on chronic spontaneous urticaria: a systematic review and meta-analysis. Antibiotics (Basel). 2021;10:156.
Henz BM ZT, Grabbe J, Monroe E. Urticaria. Clinical, diagnostic and therapeutic aspects. In: Causes of urticaria. Springer, 1998.
Ergon MC, ilknur T, Yucesoy M, Ozkan S. Candida spp. colonization and serum anticandidal antibody levels in patients with chronic urticaria. Clin Exp Dermatol. 2007;32:740-743.
Zuberbier T, Chantraine-Hess S, Hartmann K, Czarnetzki BM. Pseudoallergen-free diet in the treatment of chronic urticaria. A prospective study. Acta Derm Venereol. 1995;75:484-487.
Bruno G, Andreozzi P, Graf U. Exercise-induced urticaria-angioedema syndrome:A role in gastroesophageal reflux. In: Vena G. A. PP:Proceedings of the international symposium on urticaria.: Bari. Editrice CSH, Milan, 1998:85-89.
Zheleznov S, Urzhumtseva G, Petrova N, et al. Gastritis can cause and trigger chronic spontaneous urticaria independent of the presence of Helicobacter pylori. Int Arch Allergy Immunol. 2018;175:246-251.
Stuck BA, Gotte K, Windfuhr JP, et al. Tonsillectomy in children. Dtsch Arztebl Int. 2008;105:852-860;quiz 60-61.
Müller A, Neuber K, Metternich FU, Wenzel S. Effekt der Fokus-Tonsillektomie bei chronischen Dermatosen - Klinische Studie und Metaanalyse. Laryngorhinootologie. 2004;83:26-12.
Schulze W. Tonsillektomie zur Fokussanierung bei der Psoriasis, der atopischen Dermatitis und der chronischen Urtikaria. Staats-und Universitätsbibliothek Hamburg Carl von Ossietzky, 2012.
Varghese R, Rajappa M, Chandrashekar L, et al. Association among stress, hypocortisolism, systemic inflammation, and disease severity in chronic urticaria. Ann Allergy Asthma Immunol. 2016;116:344-348.e1.
Schut C, Magerl M, Hawro T, et al. Disease activity and stress are linked in a subpopulation of chronic spontaneous urticaria patients. Allergy. 2020;75:224-226.
Grattan CE, O'Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic „idiopathic“ urticaria. Br J Dermatol. 2000;143:365-372.
Juhlin L. Recurrent urticaria:clinical investigation of 330 patients. Br J Dermatol. 1981;104:369-381.
Pfrommer C, Bastl R, Vieths S, et al. Characterization of naturally occurring pseudoallergens causing chronic urticaria. J Allergy Clin Immunol. 1996;97:367.
Pigatto PD, Valsecchi RH. Chronic urticaria:a mystery. Allergy. 2000;55:306-308.
Bunselmeyer B, Laubach HJ, Schiller M, et al. Incremental build-up food challenge - a new diagnostic approach to evaluate pseudoallergic reactions in chronic urticaria:a pilot study:stepwise food challenge in chronic urticaria. Clin Exp Allergy. 2009;39:116-126.
Nettis E, Colanardi MC, Ferrannini A, Tursi A. Sodium benzoate-induced repeated episodes of acute urticaria/angio-oedema:randomized controlled trial. Br J Dermatol. 2004;151:898-902.
Akoglu G, Atakan N, Cakir B, et al. Effects of low pseudoallergen diet on urticarial activity and leukotriene levels in chronic urticaria. Arch Dermatol Res. 2012;304:257-262.
Wagner N, Dirk D, Peveling-Oberhag A, et al. A Popular myth - low-histamine diet improves chronic spontaneous urticaria - fact or fiction? J Eur Acad Dermatol Venereol. 2017;31:650-655.
Beissert S, Stander H, Schwarz T. UVA rush hardening for the treatment of solar urticaria. J Am Acad Dermatol. 2000;42:1030-1032.
Grob JJ, Auquier P, Dreyfus I, Ortonne JP. How to prescribe antihistamines for chronic idiopathic urticaria:desloratadine daily vs PRN and quality of life. Allergy. 2009;64:605-612.
Weller K, Ardelean E, Scholz E, et al. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol. 2013;93:168-174.
Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines:a GA(2)LEN position paper. Allergy. 2010;65:459-466.
Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160.
Kubo N, Senda M, Ohsumi Y, et al. Brain histamine H1 receptor occupancy of loratadine measured by positron emission topography:comparison of H1 receptor occupancy and proportional impairment ratio. Hum Psychopharmacol. 2011;26:133-139.
Kontou-Fili K, Paleologos G, Herakleous M. Suppression of histamine-induced skin reactions by loratadine and cetirizine diHCl. Eur J Clin Pharmacol. 1989;36:617-619.
Zuberbier T, Munzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology. 1996;193:324-327.
Kontou-Fili K, Maniakatou G, Demaka P, Paleologos G. Therapeutic effect of cetirizine 2 HCl in delayed pressure urticaria. Health Sci Rev. 1989;3:23-25.
Wanderer AA, Ellis EF. Treatment of cold urticaria with cyproheptadine. J Allergy Clin Immunol. 1971;48:366-371.
Kaplan AP, Gray L, Shaff RE, et al. In vivo studies of mediator release in cold urticaria and cholinergic urticaria. J Allergy Clin Immunol. 1975;55:394-402.
Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676-682.
Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria:a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123:672-679.
Gimenez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol. 2009;23:1088-1091.
Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria:a systematic review and meta-analysis. Br J Dermatol. 2016;175:1153-1165.
Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567-573e1.
Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128:202-209.e5.
Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines:a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67-75.
Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924-935.
Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101-109.
Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria:A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137:1742-1750.e4.
Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria:A systematic review of published evidence. J Allergy Clin Immunol. 2018;141:638-649.
Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011;154:177-180.
Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63:247-249.
Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117:1415-1418.
Metz M, Schutz A, Weller K, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140:864-867.e5.
Guzelbey O, Ardelean E, Magerl M, et al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63:1563-1565.
Bullerkotte U, Wieczorek D, Kapp A, Wedi B. Effective treatment of refractory severe heat urticaria with omalizumab. Allergy. 2010;65:931-932.
Krause K, Ardelean E, Kessler B, et al. Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy. 2010;65:1494-1495.
Maurer M, Schutz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140:870-873.e5.
Maurer M, Kaplan A, Rosén K, et al. The XTEND-CIU study:Long-term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol. 2018;141(3):1138-1139.e7.
Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients:results from X-ACT, a randomized controlled trial. Allergy. 2016;71:1135-1144.
Finlay AY, Kaplan AP, Beck LA, et al. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017;31:1715-1721.
Maurer M, Sofen H, Ortiz B, et al. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria:analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol. 2017;31:1056-1063.
Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014;150:288-290.
Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H-1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567-573.e1.
Stellato C, de Paulis A, Ciccarelli A, et al. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol. 1992;98:800-804.
Harrison CA, Bastan R, Peirce MJ, et al. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br J Pharmacol. 2007;150:509-518.
Vena GA, Cassano N, Colombo D, et al. Cyclosporine in chronic idiopathic urticaria:a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2006;55:705-709.
Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria:a meta-analysis and systematic review. J Allergy Clin Immunol Pract. 2018;6:586-599.
Zuberbier T, Ifflander J, Semmler C, Henz BM. Acute urticaria:clinical aspects and therapeutic responsiveness. Acta Derm Venereol. 1996;76:295-297.
Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria:a retrospective analysis. J Investig Allergol Clin Immunol. 2010;20:386-390.
Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline:management of urticaria. Allergy. 2009;64:1427-1443.
Rutkowski K, Grattan CEH. How to manage chronic urticaria ‘beyond’ guidelines:a practical algorithm. Clin Exp Allergy. 2017;47:710-718.
Magerl M, Philipp S, Manasterski M, et al. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol. 2007;119:752-754.
O'Donnell BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol. 1998;138:101-106.
Dawn G, Urcelay M, Ah-Weng A, et al. Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria. Br J Dermatol. 2003;149:836-840.
Pereira C, Tavares B, Carrapatoso I, et al. Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria. Eur Ann Allergy Clin Immunol. 2007;39:237-242.
Mitzel-Kaoukhov H, Staubach P, Muller-Brenne T. Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2010;104:253-258.
Bangsgaard N, Skov L, Zachariae C. Treatment of refractory chronic spontaneous urticaria with adalimumab. Acta Derm Venereol. 2017;97:524-525.
Sand FL, Thomsen SF. TNF-Alpha Inhibitors for Chronic Urticaria:Experience in 20 Patients. J Allergy (Cairo). 2013;2013:130905.
Hannuksela M, Kokkonen EL. Ultraviolet light therapy in chronic urticaria. Acta Derm Venereol. 1985;65:449-450.
Borzova E, Rutherford A, Konstantinou GN, et al. Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism:a pilot study. J Am Acad Dermatol. 2008;59:752-757.
Engin B, Ozdemir M, Balevi A, Mevlitoglu I. Treatment of chronic urticaria with narrowband ultraviolet B phototherapy:a randomized controlled trial. Acta Derm Venereol. 2008;88:247-251.
Thormann J, Laurberg G, Zachariae H. Oral sodium cromoglycate in chronic urticaria. Allergy. 1980;35:139-141.
Laurberg G. Tranexamic acid (Cyklokapron) in chronic urticaria:a double-blind study. Acta Derm Venereol. 1977;57:369-370.
Lawlor F, Ormerod AD, Greaves MW. Calcium antagonist in the treatment of symptomatic dermographism. Low-dose and high-dose studies with nifedipine. Dermatologica. 1988;177:287-291.
Lawlor F, Black AK, Ward AM, et al. Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine. Br J Dermatol. 1989;120:403-408.
Dover JS, Black AK, Ward AM, Greaves MW. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients. J Am Acad Dermatol. 1988;18:1289-1298.
Asero R, Tedeschi A, Cugno M. Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer:a pilot study. Int Arch Allergy Immunol. 2010;152:384-389.
Novak Z, Yanez A, Kiss I, et al. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. Pediatr Allergy Immunol. 2016;27:493-498.
Nayak AS, Berger WE, LaForce CF, et al. Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. Allergy Asthma Proc. 2017;38:222-230.
Gupta S, Khalilieh S, Kantesaria B, Banfield C. Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br J Clin Pharmacol. 2007;63:534-540.
Gupta SK, Kantesaria B, Banfield C, Wang Z. Desloratadine dose selection in children aged 6 months to 2 years:comparison of population pharmacokinetics between children and adults. Br J Clin Pharmacol. 2007;64:174-184.
Meltzer EO, Scheinmann P, Rosado Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis - a pooled analysis of three studies. Pediatr Allergy Immunol. 2004;15:253-260.
Pampura AN, Papadopoulos NG, Spicak V, Kurzawa R. Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease. Int Arch Allergy Immunol. 2011;155:367-378.
Potter P, Mitha E, Barkai L, et al. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. Pediatr Allergy Immunol. 2016;27:55-61.
Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol. 2008;26:19-23.
Schwarz EB Moretti ME, Nayak S, Koren G. Risk of hypospadias in offspring of women using loratadine during pregnancy:a systematic review and meta-analysis. Drug Saf. 2008;31:775-788.
Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair Pregnancy Registry (EXPECT):the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135:407-412.
González-Medina M, Curto-Barredo L, Labrador-Horrillo M, Giménez-Arnau A. Omalizumab use during pregnancy for chronic spontaneous urticaria (CsU):report of two cases. J Eur Acad Dermatol Venereol. 2017;31:e245-e246.
Ghazanfar MN, Thomsen SF. Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies. Case Rep Med. 2015;2015:368053.